SEARCH

SEARCH BY CITATION

References

  • 1
    UNOS 1996 Annual Report, The US Scientific Registry of Transplant Recipients and the Organ Procurement and Transplantation Network Data as of September 7, 1996. Richmond, VA, UNOS and the US Department of Health and Human Services, 1996.
  • 2
    UNOS official Waiting List Statistics, July 30, 1997. Available at: www.unos.org. Accessed: January 15, 2001.
  • 3
    Dodson SF, Issa S, Araya V, Gayowski T, Pinna A, Eghtesad B, et al. Infectivity of hepatic allografts with antibodies to hepatitis B virus. Transplantation 1997; 64:15821584.MEDLINE
  • 4
    Turner DPJ, Zuckerman M, Alexander GJM, Waite J, Wreghitt T. Risk of inappropriate exclusion of organ donors by introduction of hepatitis B core antibody testing. Transplantation 1997; 63:775778.MEDLINE
  • 5
    Radomski JS, Moritz MJ, Armenti VT, Munoz SJ. Hepatitis B transmission from a liver donor who tested negative for hepatitis B surface antigen and positive for hepatitis B core antibody. Liver Transpl Surg 1996; 2:130131.MEDLINE
  • 6
    Douglas DD, Rakela J, Wright TL, Krom RAF, Wiesner RH. The clincial course of transplantation-associated De Novo hepatitis B infection in the liver transplant recipient. Liver Transpl Surg 1997; 63:105111.
    Direct Link:
  • 7
    Kadian M, Hawkins K, Schwartz M, Miller C. use of hepatits B core antibody-positive multiorgan donors. J Transplant Coord 1994; 4:5760.
  • 8
    Wachs ME, Amend WJ, Ascher NL, Bretan PN, Emond J, Lake JR, et al. The risk of transmission of hepatitis B from HBsAg (−), HBcAb (+), HBIgM (−) organ donors. Transplantation 1995; 59:230234.MEDLINE
  • 9
    Dickson RC, Everhart JE, Lake JR, Wei Y, Seaberg EC, Wiesner RH, et al. Transmission of hepatitis B by transplantation of livers from donors positive for antibody to hepatitis B core antigen. Gastroenterology 1997; 113:16681674.MEDLINE
  • 10
    Dodson SF, Bonham CA, Geller DA, Cacciarelli TV, Rakela J, Fung JJ. Prevention of de novo hepatitis B infection in recipients of hepatic allografts from anti-HBc positive donors. Transplantation 1999; 68:10581061.MEDLINE
  • 11
    Prieto M, Gomez MD, Berenguer M, Cordoba J, Rayon JM, Pastor M, et al. De novo hepatitis B after liver transplantation from hepatitis B core antibody-positive donors in an area with high prevalence of anti-HBc positivity in the donor population. Liver Transpl 2001; 7:5158.MEDLINE
  • 12
    Chan M, Chang WK. Renal transplantation from HBsAg positive donors to HBsAg negative recipients. Br J Med 1988; 297:522523.
  • 13
    Lutwick LI, Sywassink JM, Corry RJ, Shorey JW. The transmission of hepatitis B by renal transplantation. Clin Nephrol 1983; 19:317319.MEDLINE
  • 14
    Wolf JL, Perkins H, Schreeder MT, Vincenti F. The transplanted kidney as a source of hepatitis B infection. Ann Intern Med 1979; 91:412413.MEDLINE
  • 15
    Madayag RM, Johnson LB, Bartlett ST, Schweitzer EJ, Constantine NT, McCarter RJ Jr, et al. Use of renal allografts from donors positive for hepatitis B core antibody confers minimal risk for subsequent development of clinical hepatitis B virus disease. Transplantation 1997; 64:17811786.MEDLINE
  • 16
    Chazouilleres O, Mamish D, Kim M, Carey K, Ferrell L, Roberts JP, et al. “Occult” hepatitis B virus as a source of infection in liver transplant recipients. Lancet 1994; 343:142146.MEDLINE
  • 17
    Crippin J, Foster B, Carlen S, Borcich A, Bodenheimer H. Retransplantation in hepatits B: A multicenter experience. Transplantation 1994; 57:823826.MEDLINE
  • 18
    Van Thiel D, El-Ashmawy L, Love K, Gavaler JS, Starel TE. Response to hepatitis B vaccination by liver transplant candidates. Dig Dis Sci 1992; 37:12451249.MEDLINE
  • 19
    Iwarson S, Tabor, E, Thomas HC, Snoy P, Gerety RJ. Protection against hepatitis B virus infection by immunization with hepatitis B core antigen. Gastroenterology 1985; 88:763767.MEDLINE
  • 20
    Markowitz J, Martin P, Conrad A, Markmann JF, Seu P, Yersiz H, et al. Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin. Hepatology 1998; 28:585589.MEDLINE
  • 21
    Boker KH, Ringe B, Kruger M, Pichlmayr R, Manns MP. Prostaglandin E plus famcyclovir: A new concept for the treatment of severe hepatitis B after liver transplantation. Transplantation 1994; 57:17061708.MEDLINE
  • 22
    McCaughan G, Angus P, Bowden S, Shaw T, Breschkin A, Sheil R, Locarnini S. Retransplantation for precore mutant-related chronic hepatitis B infection: Prolonged survival in a patient receiving sequential gancyclovir/famcyclovir therapy. Liver Transpl Surg, 2:472474, 1996.
  • 23
    Chung RT, Feng S, Delmonico FL. Approach to the management of allograft recipients following the detection of hepatitis B virus in the prospective organ donor. Am J Transpl 2001; 1:185191.
  • 24
    Kiyasu PK, Ishitani MB, McGory RW, Gaffey MJ, Dickson RC, Caldwell SH, et al. Prevention of hepatitis B recurrence after a second liver transplant: The role of maintenance polyclonal HBIG therpay. Transplantation 1994; 58:954955.MEDLINE
  • 25
    Ben-Ari Z, Shmueli D, Mor E, Shapira Z, Tur-Kaspa R. Beneficial effect of lamivudine in recurrent hepatitis B after liver transplantation. Transplantation 1997; 63:393396.MEDLINE
  • 26
    Terrault NA, Zhou S, Combs C, Hahn JA, Lake JR, Roberts JP, et al. Prophylaxis in liver transplant recipients using a fixed dosing schedule of hepatitis B immunoglobulin. Hepatology 1996; 24:13271333.MEDLINE
  • 27
    Yoshida EM, Wolber RA, Mahmood WA, Anderson FH, Scudamore CH, Erb SR. Attempted resolution of acute recurrent hepatitis B in a transplanted liver allograft by the administration of gancyclovir. Transplantation 1994; 58:956958.MEDLINE
  • 28
    Bartholomew MM, Jansen RW, Jeffers LJ, Reddy KR, Johnson LC, Bunzendahl H, et al. Hepatitis B virus resistance to lamivudine giver for recurrent infection after orthotopic liver transplantation. Lancet 1997; 349:2022.MEDLINE
  • 29
    Bain VG, Kneteman NM, Ma MM, Gutfreund K, Shapiro JA, Fischer K, et al. Efficacy of lamivudine in chronic hepatitis B patients with active viralreplication and decompensated cirrhosis undergoing liver transplantation. Transplantation 1996; 62:14561462.MEDLINE
  • 30
    Tipples GA, Ma MM, Fischer KP, Bain VG, Kneteman NM, Tyrrell DL. Mutation in HBV RNA–dependent DNA polymerase confers resistance to lamivudine in vivo. Hepatology 1996; 24:714717MEDLINE